Chitose Laboratory Corp., a provider of advanced cell line development services, and Fujifilm Biosciences Inc., a leader in the innovation and manufacture of cell culture solutions for the life science market, have formed a new strategic alliance that aims to accelerate biopharmaceutical manufacturing.

Chitose’s expertise in cell line development using CHO-MK cells aligns with Fujifilm Biosciences’ advanced culture media development and manufacturing capabilities. By combining these complementary capabilities, the alliance will help accelerate biopharmaceutical manufacturing processes and support the development of innovative solutions for the industry.

“Together, the combined expertise of Chitose and Fujifilm Biosciences is set to create comprehensive solutions that not only enhance manufacturing efficiencies but also provide an integrated approach to tackling challenges in the global biopharma landscape,” said Takayuki Horiuchi, Chief Technology Officer at Chitose Laboratory Corp.

The collaboration brings together the unique strengths of both companies to improve the way medicines are produced, supporting the development of new therapies for patients worldwide and helping more people access life-saving treatments.

“We’re excited about this strategic alliance as it underscores a shared vision of advancing therapeutic development by providing solutions designed to meet the growing demand for making biopharmaceuticals more accessible for treating conditions,” added Yutaka Yamaguchi, chairman and chief executive officer at Fujifilm Biosciences.